Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment
Introduction More than 2 million individuals in the USA have an opioid use disorder (OUD). Methadone maintenance treatment is the gold standard of medication-based treatment for OUD, but high-dose methadone is associated with cardiotoxicity and respiratory complications, among other side effects. Th...
Saved in:
Main Authors: | Annabelle M Belcher, Thomas O Cole, Aaron D Greenblatt, Stephen W Hoag, David H Epstein, Michael Wagner, Amy S Billing, Ebonie Massey, Kristen R Hamilton, Zofia K Kozak, Christopher J Welsh, Eric Weintraub, Emerson M Wickwire, Eric D Wish, Ted J Kaptchuk, Luana Colloca |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-06-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/9/6/e026604.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Accidental Overdosing in Patients with Take-Home Methadone – A Case Series
by: Anshul Sharma, et al.
Published: (2025-01-01) -
Randomization and placebo effects in clinical trials of major depressive disorder
by: James A. Rogers, et al.
Published: (2025-02-01) -
Individual Differences in Placebo Analgesia: Functional Connectivity and Neural Mechanisms [Letter]
by: Cao H, et al.
Published: (2025-02-01) -
Potential improvement in spatial accessibility of methadone treatment with integration into other outpatient substance use disorder treatment programs, New York City, 2024.
by: Marcus A Bachhuber, et al.
Published: (2025-01-01) -
Beneficial and harmful effects of duloxetine versus placebo, ‘active placebo’ or no intervention for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials
by: Christian Gluud, et al.
Published: (2025-02-01)